stockrow
Friday 6 November 2026
Export BBNX’s income statement to Excel — free account
Beta Bionics, Inc.
BBNX Healthcare Medical Devices
Beta Bionics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $100.3 million, up 53.9% from fiscal 2024.
- Revenue
- +30.3%
- EPS
- −58.6%
- Free cash flow
- −45.5%
Quarter to September 2026, against a year earlier
15.72
0.23
+1.48%
Follow BBNX
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
6.94 | 5.87 | 4.04 | 12.32 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(71.89) | (47.74) | (18.68) | (143.15) | |
P/B ratio |
2.20 | 2.72 | 1.64 | 4.29 | |
Price to Tangible BV |
2.20 | 2.72 | 1.64 | 4.29 | |
EV/Sales |
5.05 | 4.35 | 2.23 | 10.13 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(10.83) | (9.27) | (4.48) | (19.94) | |
EV/FCF |
(1.88) | (1.53) | (0.73) | (3.05) | |
Quick Ratio |
7.95 | 7.64 | 9.29 | 7.64 | |
Current Ratio |
8.92 | 8.88 | 10.69 | 8.66 | |
Net Debt/EBITDA |
9.52 | 7.44 | 8.57 | 16.66 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.33 | 0.38 | 0.34 | 0.42 | |
Operating CF/Net income |
0.50 | 0.62 | 1.09 | 0.64 | |
Capex/Depreciation |
(1.68) | (0.80) | (1.40) | (94.01) | |
Research and Development Expense of Revenue |
33.73% | 31.99% | 37.49% | 31.54% | |
Selling, General and Administrative Expense of Revenue |
98.48% | 106.96% | 109.87% | 77.63% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
18.91% | 21.92% | 19.57% | 13.40% | |
Graham Net Nets |
0.28 | 0.28 | 0.48 | 0.18 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(9.71%) | (10.53%) | (15.07%) | (6.40%) | |
Free Cash Flow Yield |
(38.79%) | (48.44%) | (75.88%) | (26.96%) | |
Revenue per Share |
0.76 | 0.72 | 0.62 | 0.79 | |
Operating CF per Share |
(0.26) | (0.33) | (0.54) | (0.21) | |
Capex per Share |
(0.05) | (0.02) | (0.03) | (6.88) | |
Free Cash Flow per Share |
(0.31) | (0.35) | (0.57) | (7.09) | |
Cash per Share |
5.16 | 4.05 | 4.49 | 5.41 | |
Shareholders Equity per Share |
8.62 | 5.76 | 6.10 | 7.10 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
8.62 | 5.76 | 6.10 | 7.10 | |
Free Cash Flow |
(14.56) | (15.66) | (25.21) | (287.27) | |
Working Capital |
260.11 | 205.02 | 224.80 | 236.98 | |
Capital Expenditures |
(2.27) | (1.04) | (1.38) | (278.64) | |
Net Current Asset Value |
250.57 | 195.01 | 214.81 | 226.77 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.06 | 0.03 | 0.05 | 8.67 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
16.10 | 14.72 | 12.41 | 14.56 | |
Average Payables |
4.57 | 4.39 | 2.89 | 3.93 | |
Average Inventory |
21.67 | 20.62 | 19.73 | 17.52 | |
Average Assets |
386.90 | 311.18 | 321.22 | 239.19 | |
Average Common Equity |
348.07 | 279.00 | 292.50 | 21.13 |
Columns are period end dates · fundamentals updated 2 Nov 2026